Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MRNA stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/S.
Implied fair value · at MRNA's multiple
Needs MRNA P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Illumina, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
MRNA vs PFE
JOHNSON & JOHNSON
MRNA vs JNJ
GILEAD SCIENCES, INC.
MRNA vs GILD
AMGEN INC
MRNA vs AMGN
NOVAVAX INC
MRNA vs NVAX
VERTEX PHARMACEUTICALS INC / MA
MRNA vs VRTX
THERMO FISHER SCIENTIFIC INC.
MRNA vs TMO
AGILENT TECHNOLOGIES, INC.
MRNA vs A
DANAHER CORP /DE/
MRNA vs DHR
BIO-RAD LABORATORIES, INC.
MRNA vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
MRNA vs PACB
Natera, Inc.
MRNA vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MRNA can stabilize revenue and materially improve profitability from the current deeply negative margin profile, then avoid selling aggressively; otherwise, ILMN-relative valuation and weak operating metrics favor a cautious or underweight stance because the stock trades above ILMN-implied value despite much weaker fundamentals.
MRNA’s current price of $53.86 is well above ILMN-implied price of $33.15, implying 38.4% downside on the provided P/S-based valuation. The stock is also near the top of its historical band, which suggests the market is already pricing in a relatively favorable outcome despite weak current operating results.
Supporting Metrics
